German Biotech Clears Phase I with New Gene Therapy for Glaucoma – Labiotech.eu (blog)
|
German Biotech Clears Phase I with New Gene Therapy for Glaucoma
Labiotech.eu (blog) Isarna Therapeutics showed off positive Phase I data for its lead compound ISTH0036 in patients with Glaucoma at the ARVO meeting last week. Isarna Therapeutics from Munich is developing TGF-β specific antisense RNA therapeutics to treat ophthalmic … |
|
German Biotech Clears Phase I with New Gene Therapy for Glaucoma
Labiotech.eu (blog) Isarna Therapeutics showed off positive Phase I data for its lead compound ISTH0036 in patients with Glaucoma at the ARVO meeting last week. Isarna Therapeutics from Munich is developing TGF-β specific antisense RNA therapeutics to treat ophthalmic … |
|
ToolGen, Inc. Announces Poster Presentation on Genome Editing of Human T Cells at 2017 American Society for Gene …
P&T Community The poster presentation entitled “Genome editing of human T cells to generate CAR–T cells with enhanced antitumor function” aimed to study the proposed idea that T-cell anergy serves to induce dysfunction in a wide variety of tumor microenvironments. |
|
ToolGen, Inc. Announces Poster Presentation on Genome Editing of Human T Cells at 2017 American Society for Gene …
P&T Community The poster presentation entitled “Genome editing of human T cells to generate CAR–T cells with enhanced antitumor function” aimed to study the proposed idea that T-cell anergy serves to induce dysfunction in a wide variety of tumor microenvironments. |
|
ToolGen, Inc. Announces Poster Presentation on Genome Editing of Human T Cells at 2017 American Society for Gene …
PharmiWeb.com (press release) The poster presentation entitled “Genome editing of human T cells to generate CAR–T cells with enhanced antitumor function” aimed to study the proposed idea that T-cell anergy serves to induce dysfunction in a wide variety of tumor microenvironments. |